– SWITZERLAND, Schlieren – Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines, announced the appointments of Christina Ackermann and Tim Ramdeen to its Board of Directors. Christina Ackermann succeeds Harry Welten as Board Chair.
“Christina and Tim are exceptional leaders. Their broad expertise across commercial and legal affairs as well as their network among investors will be key as we prepare for the next development steps of our serotype-independent vaccine candidates,” said CEO Anna Sumeray. “We look forward to working with Christina and Tim and we will greatly benefit from their business acumen and broad networks as we advance our pipeline towards the next key milestones.”
About Christina Ackermann
Christina Ackermann brings over 27 years of legal and management experience across the pharmaceutical, device, and consumer products industries. She was instrumental in establishing various global legal functions, strategic initiatives, and transactions at Bausch + Lomb, Novartis, Bristol-Myers Squibb, and DuPont.
She serves as a non-executive member of the boards of Verona Pharma plc (NASDAQ: VRNA), Oculis Holding AG (NASDAQ: OCS), and private boards/NGOs.
Christina Ackermannholds a Post Graduate Diploma in EC Competition Law from King’s College at the University of London, UK, and an LLB from Queen’s University, Kingston, Canada.
About Tim Ramdeen
Tim Ramdeen has nearly a decade of experience in private equity, hedge fund investing, capital markets, and company formation. Since 2022, he has been the founder and managing partner of Dharma Capital Advisors. Tim Ramdeen serves as a non-executive member of the boards of Onconetix Inc. (NASDAQ: ONCO) and Entero Therapeutics Inc. (NASDAQ: ENTO).
Tim Ramdeen received his B.S. in Biology from Temple University. Additionally, he earned his MBA in Finance from the NYU Stern School of Business.
About Virometix
Virometix AG is a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer. There is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix’ proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy, ease and cost of manufacturing and stability.
For more: https://virometix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.